| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
SP-4206 targets the interaction between interleukin-2 (IL-2) and its alpha receptor subunit IL-2Rα (CD25). By binding to IL-2 with high affinity (Kd = 70 nM), SP-4206 blocks IL-2 from binding to IL-2Rα (Kd = 10 nM), thereby disrupting IL-2/IL-2R signaling.
|
|---|---|
| ln Vitro |
SP4206 binds to WT IL-2, IL-2 variation K35L/M39V, IL-2 variant P65A, and IL-2 variant V69A with EC50s of 68.8, 80.1, 117.0, and 10.4 nM, respectively [1].
SP-4206 binds to IL-2 with high affinity (Kd = 70 nM) and blocks the binding of IL-2 to its receptor IL-2Rα (Kd = 10 nM). The compound's ability to disrupt the IL-2/IL-2Rα interaction makes it a valuable tool for studying IL-2 signaling and its role in immune regulation. |
| ln Vivo |
Specific in vivo efficacy data for SP-4206 are not extensively detailed in standard reference sources. As an inhibitor of IL-2/IL-2Rα interaction, it would be expected to modulate immune responses in vivo. Studies in animal models of autoimmune diseases or cancer immunotherapy would be required to fully characterize its in vivo effects.
|
| Enzyme Assay |
SP-4206's binding to IL-2 can be assessed using in vitro binding assays such as surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC). Recombinant IL-2 is immobilized on a sensor chip or in a calorimetry cell, and increasing concentrations of SP-4206 are flowed over or titrated to measure binding affinity (Kd). Competition binding assays with labeled IL-2 can also be performed to assess the compound's ability to block IL-2/IL-2Rα interaction.
|
| Cell Assay |
The cellular activity of SP-4206 is evaluated in IL-2-dependent cell lines such as CTLL-2 cells. Cells are treated with increasing concentrations of SP-4206 in the presence of IL-2. Cell proliferation is measured using [³H]-thymidine incorporation or MTT assays. The ability of SP-4206 to inhibit IL-2-induced STAT5 phosphorylation is assessed by Western blot or flow cytometry.
|
| Animal Protocol |
Specific in vivo animal experimental protocols for SP-4206 are not extensively detailed in standard reference sources. For evaluating its immunomodulatory effects, SP-4206 would be administered to mouse models of autoimmune diseases or tumor-bearing mice. Immune cell populations, cytokine levels, and tumor growth would be assessed to evaluate efficacy.
|
| ADME/Pharmacokinetics |
SP-4206 has a molecular formula of C30H37Cl2N7O6 and a molecular weight of 662.56 g/mol. It binds to IL-2 with high affinity (Kd = 70 nM). Specific pharmacokinetic parameters such as half-life, bioavailability, and plasma protein binding are not extensively detailed.
|
| Toxicity/Toxicokinetics |
The toxicity profile of SP-4206 is not extensively documented. As a modulator of IL-2 signaling, potential adverse effects may include immunosuppression. Specific LD50 values and organ-specific toxicity data are not readily available.
|
| References | |
| Additional Infomation |
N(2)-Carbamoyl-N-{2-[4-(3-{4-[(5-carboxyfuran-2-yl)methoxy]-2,3-dichlorophenyl}-1-methyl-1H-pyrazol-5-yl)piperidin-1-yl]-2-oxoethyl}-D-leucine is a leucine derivative prepared by the condensation reaction of the secondary amino group of 5-({2,3-dichloro-4-[1-methyl-5-(piperidin-4-yl)-1H-pyrazol-3-yl]phenoxy}methyl)-2-furancarboxylic acid with the carboxyl group of N-amidinyl-L-leucine. It belongs to the guanidine, furancarboxylic acid, pyrazolylpiperidine, glycine derivative, dichlorobenzene, and D-leucine derivative classes.
SP-4206 (CAS# 515846-21-6) is a potent IL-2/IL-2Rα interaction inhibitor. It binds to IL-2 with high affinity (Kd = 70 nM) and blocks IL-2 binding to IL-2Rα (Kd = 10 nM). The compound is a valuable chemical probe for immunology and cancer immunotherapy research. |
| Molecular Formula |
C30H37CL2N7O6
|
|---|---|
| Molecular Weight |
662.564084768295
|
| Exact Mass |
661.218
|
| CAS # |
515846-21-6
|
| Related CAS # |
515846-21-6;515846-79-4 (xTFA);716371-43-6 (TFA);
|
| PubChem CID |
5288251
|
| Appearance |
White to light yellow solid powder
|
| LogP |
3.4
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
45
|
| Complexity |
1060
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
ClC1C(=C(C=CC=1C1C=C(C2CCN(C(CNC([C@@H](CC(C)C)/N=C(\N)/N)=O)=O)CC2)N(C)N=1)OCC1=CC=C(C(=O)O)O1)Cl
|
| InChi Key |
VNZHOIDQBPFEJU-OAQYLSRUSA-N
|
| InChi Code |
InChI=1S/C30H37Cl2N7O6/c1-16(2)12-21(36-30(33)34)28(41)35-14-25(40)39-10-8-17(9-11-39)22-13-20(37-38(22)3)19-5-7-23(27(32)26(19)31)44-15-18-4-6-24(45-18)29(42)43/h4-7,13,16-17,21H,8-12,14-15H2,1-3H3,(H,35,41)(H,42,43)(H4,33,34,36)/t21-/m1/s1
|
| Chemical Name |
5-[[2,3-dichloro-4-[5-[1-[2-[[(2R)-2-(diaminomethylideneamino)-4-methylpentanoyl]amino]acetyl]piperidin-4-yl]-1-methylpyrazol-3-yl]phenoxy]methyl]furan-2-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~150.93 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.14 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.14 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.14 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5093 mL | 7.5465 mL | 15.0930 mL | |
| 5 mM | 0.3019 mL | 1.5093 mL | 3.0186 mL | |
| 10 mM | 0.1509 mL | 0.7546 mL | 1.5093 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
